Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib

The Bruton tyrosine kinase (BTK) inhibitor ibrutinib has excellent clinical activity in patients with chronic lymphocytic leukemia (CLL). Characteristically, ibrutinib causes CLL cell redistribution from tissue sites into the peripheral blood during the initial weeks of therapy. To better characteri...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Wodarz, Dominik, Garg, Naveen, Komarova, Natalia L., Benjamini, Ohad, Keating, Michael J., Wierda, William G., Kantarjian, Hagop, James, Danelle, O’Brien, Susan, Burger, Jan A.
Format: Artigo
Sprog:Inglês
Udgivet: American Society of Hematology 2014
Fag:
Lymphoid Neoplasia
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4123432/
https://ncbi.nlm.nih.gov/pubmed/24829205
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-02-554220
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker